ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
9.34
+0.10 (1.08%)
At close: Dec 16, 2025, 4:00 PM EST
9.10
-0.24 (-2.57%)
After-hours: Dec 16, 2025, 7:57 PM EST
ProMIS Neurosciences Employees
As of December 31, 2024, ProMIS Neurosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,660,408
Market Cap
20.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | 5 | 500.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PMN News
- 6 days ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 15 days ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 15 days ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 7 weeks ago - ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310 - GlobeNewsWire